Search

1 to 10 of 788
Sort by

Event
SITC CPG Webinar – Case Studies in Immune Checkpoint Inhibitor-related Adverse Events

This webinar is supported, in part, by independent medical education grant funding from Amgen and Merck & Co., Inc. (as of 6/7/21) #ImmuneCheckpointInhibitors #AdverseEvents

 10-06-2021 | 19:00 - 20:00 ET


Event
CPG Webinar – Practical Management Pearls for Immune Checkpoint Inhibitor-related Adverse Events

This webinar is supported, in part, by independent medical education grant funding from Amgen and Merck & Co., Inc. (as of 6/7/21) #ImmuneCheckpointInhibitors #ClinicalPracticeGuideline #AdverseEvents

 09-16-2021 | 11:30 - 12:30 ET



Library Entry
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma

Combining inhibitors of vascular endothelial growth factor and the programmed cell death protein 1 (PD1) pathway has shown efficacy in multiple cancers, but the disease-specific and agent-specific mechanisms of benefit remain unclear. The authors examined the efficacy and defined the mechanisms...


Library Entry
Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab

Colitis is one of the common immune-related adverse events that leads to morbidity and treatment discontinuation of immunotherapy. The clinical presentation, endoscopic and histopathological features and best management of this toxicity are not well defined. The authors conclude that clinically...


Library Entry
Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy

The authors have aimed to assess the impact of genomic human leukocyte antigen (HLA)-I/II homozygosity on the survival benefit of patients with unresectable locally advanced, metastatic non-small lung cancer treated by single-agent programmed cell death protein-1/programmed death ligand 1 (PD1...


Library Entry
Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer

Recent research suggests that baseline body mass index (BMI) is associated with response to immunotherapy. In this study, the authors tested the hypothesis that worsening nutritional status prior to the start of immunotherapy, rather than baseline BMI, negatively impacts immunotherapy response....


Library Entry
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma

To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with the programmed cell death-1 (PD-1) antagonist pembrolizumab. The authors conclude that efti was well tolerated in...


Library Entry
Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy

To date, no systemic therapy, including immunotherapy, exists to improve clinical outcomes in metastatic uveal melanoma (UM) patients. To understand the role of immune infiltrates in the genesis, metastasis, and response to treatment for UM, the authors systematically characterized immune...


Library Entry
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study

Obesity is a risk factor for malignancy; however, its prognostic role in patients with metastatic melanoma is controversial. The authors aim to investigate the prognostic role of body mass index (BMI) in patients with metastatic melanoma receiving mitogen-activated pathway kinase inhibitors ...